{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:41:46Z","timestamp":1792500106972,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15893-8","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:17:37Z","timestamp":1774433857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Adriana Castelo Caracas","family":"de Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thacio Albuquerque Bezerra","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Benfatti","family":"Olivato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-8251","authenticated-orcid":false,"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"3","key":"15893_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"15893_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"15893_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00261-017-1209-1","volume":"43","author":"A Tang","year":"2018","unstructured":"Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol (NY). 2018;43(1):13\u201325.","journal-title":"Abdom Radiol (NY)"},{"issue":"5","key":"15893_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/cam4.4530","volume":"11","author":"J Yang","year":"2022","unstructured":"Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, et al. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med. 2022;11(5):1357\u201370.","journal-title":"Cancer Med"},{"issue":"5","key":"15893_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2023.01.033","volume":"164","author":"MR Toh","year":"2023","unstructured":"Toh MR, Wong EYT, Wong SH, Ng AWT, Loo LH, Chow PK, et al. Global Epidemiology and Genetics of Hepatocellular Carcinoma. Gastroenterology. 2023;164(5):766\u201382.","journal-title":"Gastroenterology"},{"issue":"Suppl 19","key":"15893_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00535-008-2251-0","volume":"44","author":"T Umemura","year":"2009","unstructured":"Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl 19):102\u20137.","journal-title":"J Gastroenterol"},{"issue":"1","key":"15893_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.","journal-title":"Nat Reviews Disease Primers"},{"key":"15893_CR8","doi-asserted-by":"publisher","unstructured":"Hatzidakis A, M\u00fcller L, Krokidis M, Kloeckner R. Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers (Basel). 2022;14(10):2469. https:\/\/doi.org\/10.3390\/cancers14102469.","DOI":"10.3390\/cancers14102469"},{"issue":"4","key":"15893_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"10126","key":"15893_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"10","key":"15893_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3748\/wjg.v29.i10.1551","volume":"29","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana T, Leowattana P. Systemic treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2023;29(10):1551\u201368.","journal-title":"World J Gastroenterol"},{"issue":"20","key":"15893_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"17suppl","key":"15893_CR13","doi-asserted-by":"publisher","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","volume":"42","author":"PR Galle","year":"2024","unstructured":"Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. J Clin Oncol. 2024;42(17suppl):LBA4008\u20134008.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15893_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"10408","key":"15893_CR15","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"12","key":"15893_CR16","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"8","key":"15893_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008.","journal-title":"Lancet Oncol"},{"key":"15893_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"15893_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane hand-book for systematic reviews of interventions","author":"JPTTJ Higgins","year":"2019","unstructured":"Higgins JPTTJ, Chandler J, et al. Cochrane hand-book for systematic reviews of interventions. 2nd ed. Chichester (UK): Jonh Wiley & Sons; 2019.","edition":"2"},{"issue":"20","key":"15893_CR20","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105\u201324.","journal-title":"Stat Med"},{"issue":"4","key":"15893_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A, MetaInsight. An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Synthesis Methods. 2019;10(4):569\u201381.","journal-title":"Res Synthesis Methods"},{"key":"15893_CR22","doi-asserted-by":"crossref","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","DOI":"10.1016\/j.jhep.2021.11.030"},{"issue":"1","key":"15893_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","volume":"11","author":"CE Onesti","year":"2019","unstructured":"Onesti CE, Fr\u00e8res P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment. J Thorac Dis. 2019;11(1):35\u20138.","journal-title":"J Thorac Dis"},{"key":"15893_CR24","doi-asserted-by":"crossref","unstructured":"Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, et al. HIMALAYA investigators. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35(5):448\u201357.","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"15893_CR25","doi-asserted-by":"crossref","unstructured":"Finn RS, et al. Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. J Clin Oncol. 2024;42:482\u2013482.","DOI":"10.1200\/JCO.2024.42.3_suppl.482"},{"key":"15893_CR26","doi-asserted-by":"crossref","unstructured":"Vogel A, et al. Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): final overall survival analysis of the phase 3 CARES-310 study. J Clin Oncol. 2024;42:4110\u20134110.","DOI":"10.1200\/JCO.2024.42.16_suppl.4110"},{"key":"15893_CR27","doi-asserted-by":"publisher","first-page":"175883592210968","DOI":"10.1177\/17588359221096877","volume":"14","author":"Y Guan","year":"2022","unstructured":"Guan Y, Feng D, Yin B, Li K, Wang J. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Ther Adv Med Oncol. 2022;14:17588359221096877.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"15893_CR28","doi-asserted-by":"publisher","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020;6(12):e204930.","journal-title":"JAMA Oncol"},{"issue":"7","key":"15893_CR29","doi-asserted-by":"publisher","first-page":"e2222721","DOI":"10.1001\/jamanetworkopen.2022.22721","volume":"5","author":"CD Griffiths","year":"2022","unstructured":"Griffiths CD, Zhang B, Tywonek K, Meyers BM, Serrano PE. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(7):e2222721.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"15893_CR30","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","volume":"31","author":"F Safri","year":"2024","unstructured":"Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 2024;31(8):1105\u201312.","journal-title":"Cancer Gene Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15893-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:41:46Z","timestamp":1777938106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15893"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15893-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"564"}}